Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 for prevention and severity reduction of COVID-19 in high-risk adults
ACTRN12620000707965Phase 3Withdrawn
- Sponsor
- Accelagen
- Start
- Jun 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing VPM1002 with Placebo (2 arms). Primary endpoints: Incidence of symptomatic SARS-CoV-2/COVID-19 infection and Incidence of severe laboratory-confirmed COVID-19. Planned start Jun 2020; status: withdrawn.
02
Drugs
VPM1002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000707965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000707965.